INTRODUCTION Breast cancer treatment costs are rising, and identification of high-value oncology treatment strategies is increasingly needed.
Identification of high-value cancer treatment strategies is critically important to maintaining excellence in cancer care while reducing health care expenditures.
Thus, use of P. putida for expression of PKS/NRPS systems can be considered as a valuable option for the identification of high-value compounds and the elucidation of their biosynthetic pathways.
Over the last decade, the genome-scale metabolic models have been playing increasingly important roles in elucidating metabolic characteristics of biological systems for a wide range of applications including, but not limited to, system-wide identification of drug targets and production of high value biochemical compounds.
In addition the identification and extraction of higher value products, prior to AD, is advisable, as is the quantification of how the prior extraction affects biogas yield.
While the identification of High Nature Value (HNV) farmland is possible using the different types of spatial information categories available at European scale, most data used is still too coarse and therefore only provides an approximate estimate of the presence of HNV farmland.
This application allows the identification of the following types of association: concentrations of high values (high high, HH); concentrations of low values (low low, LL); and spatial outliers (low high, LH and high low, HL).
This entails broad-scale strategies for conserving biodiversity and advocates for the identification of high conservation-value regions that are significant in a global or continental context and that could underpin more detailed conservation assessments towards such areas.
We also highlight how the CRISPR/Cas9 system can affect the next generation of drugs by accelerating the identification and validation of high-value targets.
According to their results, baseline CA 15-3 might be value in the identification of higher risk of relapse, where adjuvant chemotherapy must be introduced.
